Phase I clinical trial in healthy adult  Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector)  –  108, all, 18–60  Prevention  Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old